Susan H. Tousi

Susan Tousi is a pioneering leader and visionary in the field of biotechnology, renowned for her expertise in driving innovation and advancing healthcare solutions. As the CEO of DELFI Diagnostics, she spearheads a groundbreaking company dedicated to revolutionizing cancer detection and treatment through cutting-edge technology.

With a distinguished background in molecular biology and diagnostics, Tousi brings over two decades of experience to her role at DELFI. She earned her Bachelor of Science degree in Molecular and Cell Biology from the University of California, Berkeley, laying the foundation for her illustrious career in the life sciences industry.

Prior to joining DELFI Diagnostics, Susan held various leadership positions at Illumina, a global leader in genomics and sequencing technology. During her tenure, she played a pivotal role in driving the company's strategic initiatives and product development efforts, contributing to significant advancements in genomic medicine.

Under Tousi's guidance, DELFI Diagnostics has emerged as a trailblazer in liquid biopsy technology, leveraging the power of machine learning and artificial intelligence to detect cancer with unprecedented accuracy and efficiency. Through the company's innovative approach, she aims to revolutionize cancer care by enabling early detection, personalized treatment, and improved patient outcomes.